Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Fludarabine + Cytarabine in MCL
NCT03016988Phase 2Unknown
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL). Status: unknown.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03016988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016988.